



Vaccines and Global Health: The Week in Review
11 January 2025 :: Issue 781
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

:: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Epidemic Preparedness

Secretary-General's message on the International Day of Epidemic Preparedness

27 December 2024

COVID-19 was a wake-up call to the world. Millions of lives lost, economies shattered, health systems pushed to the brink and daily life upended for all of humanity.

The crisis may have passed, but **a harsh lesson remains: the world is woefully unprepared for the next pandemic. Outbreaks of mpox, cholera, polio and Marburg are startling reminders that infectious diseases remain a real and present danger to every country.**

On this International Day of Epidemic Preparedness, I call on countries to heed the lessons of past health emergencies to help prepare for the next.

This means building resilient public and primary health care systems and making good on the promise of Universal Health Coverage. **It means making bold investments in pandemic monitoring, detection and response. And it means ensuring equitable access to life-saving tools like vaccines, treatments and diagnostics.**

Most of all, it means global solidarity. I **call on countries to deliver on the historic Pandemic Agreement** to ensure the world works better, together, to prevent and contain future pandemics.

Today, and every day, let's commit to working together for a safer and healthier world for everyone, everywhere.

.....
.....

Featured Journal Content

The Lancet

Jan 11, 2025 Volume 405 Number 10473 p97-172

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

Infectious diseases in 2025: a year for courage and conviction

The Lancet

"The COVID-19 crisis may have passed, but a harsh lesson remains: the world is woefully unprepared for the next pandemic", said António Guterres, UN Secretary-General, on the International Day of Epidemic Preparedness, Dec 24, 2024. His remarks resonated with those of **WHO Director-General Tedros Adhanom Ghebreyesus when asked whether the world is better prepared for the next pandemic. He noted that while some painful lessons have been learnt, many of the same weaknesses and vulnerabilities that allowed COVID-19 to gain a foothold 5 years ago still exist.**

There are plenty of causes for concern, not least highly pathogenic avian influenza A (H5N1) virus infections in adults, which is causing major concern in global health circles. H5N1 has already resulted in one death in Louisiana, USA with suboptimal personal protective equipment use reported among occupationally exposed individuals.

Several key events in 2025, however, present important opportunities to act on infectious diseases. The decisions made this year will have far-reaching implications for pandemics and global health more broadly.

May, 2025 is the deadline for WHO Member States to conclude their protracted negotiations on a Pandemic Agreement at the World Health Assembly. The Agreement, aimed at preventing, preparing for, and responding to pandemics, is critically important for addressing COVID-19 and future pandemics. **However, countries have been unable to reach consensus,** particularly on contentious issues such as the sharing of pathogen information and essential technologies such as vaccines and treatments. Reaching a position of solidarity is undoubtedly challenging in an increasingly fragmented world, **but if the agreement fails, it will represent a massive failure for global health and could substantially damage the credibility of WHO** as an effective multilateral health agency.

In March, Gavi's 2025 High-Level Pledging Summit will be co-hosted by the EU and the Bill & Melinda Gates Foundation. Gavi, which plays a crucial role in increasing access to immunisation in low-income countries, is seeking to raise at least US\$9 billion to fund its most ambitious strategy for 2026–30 (Gavi 6.0): protecting 500 million children; saving at least an additional 8–9 million lives from 2026 to 2030; and boosting global health security by responding to 150 disease outbreaks. A fully funded Gavi is a vital pillar of global health, safeguarding immunisation coverage, reducing health inequities, and preventing disease incidence and child mortality, particularly in low-income countries.

The Global Fund to Fight AIDS, Tuberculosis and Malaria is also expected to launch its eighth replenishment fundraising cycle this year. The requested amount is likely to go beyond the minimum \$18 billion target of the seventh replenishment. But with changes in the US administration—the largest donor to the Global Fund—there is uncertainty about whether funding commitments will be met. The US President's Emergency Plan for AIDS Relief (PEPFAR) confronts similar concerns amid political wrangling over the organisation: its temporary reauthorisation by the US Government expires in March, 2025.

In an environment of fiscal tightening, governments may be inclined to adopt a short-term perspective in which global health slips further down their political priorities. But global health investments deliver an incredible return on investment that justifies continued commitment.

Gavi, since 2000, has protected more than 1·1 billion children, saved 18·8 million lives, and generated more than \$250 billion in economic benefits for lower-income economies. GAVI 6.0 is projected to generate at least \$100 billion in economic benefits for Gavi-implementing countries. Similarly, the Global Fund has reduced deaths from HIV, tuberculosis, and malaria by 61% since 2002 and saved 65 million lives. As the largest multilateral grants provider for resilient and sustainable health systems, the Global Fund has also invested substantially—\$1·8 billion alone in 2023—to strengthen health systems not only for combating HIV, tuberculosis, and malaria, but also to prepare against other threats such as spreading antimicrobial resistance and climate change.

Threats from infectious disease have not been vanquished; they have—in some instances at least—been tamed, but are ready to surge back, should we allow them to do so through complacency. 2025 is not the time to falter; it is the time to reaffirm commitments to global health

and wellbeing, to put into practice the lessons of COVID-19, to strengthen solidarity, and to ensure that the world can confront the health challenges we all face. Making this vision a reality is possible, with enough courage and conviction.

.....
.....

One Health

U.S. Government Releases First National One Health Plan to Protect People, Animals, and Our Environment from Shared Health Threats

Jan 10, 2025

The Centers for Disease Control and Prevention (CDC), the U.S. Department of Agriculture (USDA), and the Department of the Interior (DOI) today released the first-ever National One Health Framework to Address Zoonotic Diseases and Advance Public Health Preparedness in the United States... The framework seeks to inform One Health collaboration across the U.S. government for the next five years, describing a common vision, mission, and goals for key federal partners involved in implementing the One Health approach to address zoonotic diseases within the United States...

National One Health Framework to Address Zoonotic Diseases and Advance Public Health Preparedness in the United States – 2025-2029

U.S. Department of Health and Human Services [CDC]; U.S. Department of the Interior [Public Safety, Resource Protection and Emergency Services]; U.S. Department of Agriculture [Animal and Plant Health Inspection Service]

January 2025 :: 15 pages

PDF: https://www.cdc.gov/one-health/media/pdfs/2025/01/354391-A-NOHF-ZOONOSSES-508_FINAL.pdf

[Excerpts]

Guiding Principles

Health Equity: Health equity is the state in which everyone has a fair and just opportunity to attain their highest level of health. Achieving health equity requires focused and ongoing societal efforts to address historical and contemporary injustices, overcome obstacles to health and healthcare, and eliminate preventable health differences adversely affecting socially, economically, or environmentally disadvantaged groups.² Multisectoral efforts are needed to actively promote policies, systems, and overall community conditions that enable optimal health for all and seek to remove systemic and structural barriers that have resulted in health inequities.³

Sustainability: Everything that we need for our survival and well-being depends, either directly or indirectly, on our natural environment. To pursue sustainability is to create and maintain the conditions under which humans, animals, and environment can exist in productive harmony to support present and future generations in addition to mitigating risks that threaten sustainability.

Stewardship: Stewardship and the responsibility of humans to adopt behaviors to provide responsible solutions that recognize the importance of animal health and welfare and the integrity of the whole ecosystem is integral to securing the well-being of current and future generations.

Multisectoral and Transdisciplinary Collaboration: Engaging all relevant sectors and disciplines, including efforts by federal partners, involved in implementing the One Health approach to address zoonotic diseases and other priority One Health issues.

Goals and Objectives *[each goal below includes several Objectives, full text available at the title link above]*

- Goal #1: Coordination, Collaboration, and Communication:** Establish a standing, formal One Health coordination mechanism, the U.S. One Health Coordination Unit, to provide a common platform and governance structure to address One Health needs.
- Goal #2: Prevention:** Strengthen existing and identify new opportunities for One Health collaboration to prevent, respond to, and control zoonotic diseases, and to address early prevention, including spillover and spillback.
- Goal #3: Preparedness:** Strengthen One Health collaborations for preparedness and build new approaches where needed to address priority, endemic, emerging, and reemerging zoonotic diseases and other priority One Health issues to optimize the health and sustainability of people, animals, plants, and ecosystems.
- Goal #4: Coordinated Outbreak Investigation, Response, and Recovery:** Build and strengthen the One Health approach to coordinate zoonotic disease outbreak investigation, response, and recovery across relevant sectors.
- Goal #5: Surveillance:** Strengthen coordinated surveillance and information sharing for zoonotic disease surveillance and other One Health-relevant surveillance and reporting systems across sectors.
- Goal #6: Laboratory:** Strengthen One Health laboratory capacity (e.g., trained personnel and use of advanced laboratory techniques), coordination, research, and reporting for detection of priority, endemic, emerging, and reemerging zoonotic diseases and other priority One Health issues.
- Goal #7: Workforce:** Support and expand efforts to develop a qualified, diverse, equitable, and inclusive One Health workforce to address zoonotic disease threats.

Conclusion

Implementing the One Health approach means **involving all relevant sectors concerning human, animal, plant, and environmental health to address health concerns in a more collaborative, effective, efficient, and sustainable manner** than each sector approaching these issues alone. The National One Health Framework to Address Zoonotic Diseases and Advance Public Health Preparedness in the United States will inform One Health work across the U.S. Government, strengthen cooperative efforts to address the threat of zoonotic diseases, and advance public health preparedness.

This framework will also strengthen federal collaborations with state, Tribe, local, territorial, international, non-governmental, academic, and private sector partners.

Although the NOHF- Zoonoses is primarily focused on zoonotic diseases, the partnerships, systems, and lessons learned from the proposed activities can be expanded and applied to other priority One Health issues and shared priorities. The activities described in this framework are intended to support and encourage collaboration and cooperation with existing efforts, initiatives, and plans rather than create a parallel set of activities and priorities over the next five years (2025-2029).

At the end of the five-year period, collaborating federal agencies may determine whether to renew their commitment to this framework or update the goals and objectives. Future work needed to support the framework's objectives, including evaluation efforts and gap analyses, will be conducted within the five-year period.

.....

mPox – PHEIC

[Multi-country outbreak of mpox, External situation report #45 - 11 January 2025](#)

Overview

This is the 45th situation report for the multi-country outbreak of mpox, which provides details on the latest epidemiological trends. The outbreak of clade Ib monkeypox virus (MPXV) continues predominantly in the Democratic Republic of the Congo, Burundi and Uganda, with new travel-related cases identified in previously unaffected countries. Recent travel-associated mpox cases highlight the risk of undetected transmission in countries, emphasizing the need for strengthened surveillance and timely reporting to improve global monitoring and prevent international spread.



Mpox: Multi-country External Situation Report no.45

Mpox

Multi-country external situation report no. 45, published 11 January 2025

KEY FIGURES		
Reporting period: last 6 weeks, 25 November 2024 – 5 January 2025		
Main countries with clade Ib	Number of reported confirmed cases	Number of deaths among confirmed cases
Democratic Republic of the Congo ¹	2464	5
Burundi	798	0
Uganda	767	8
Rwanda	17	0
Kenya	12	0

Highlights

- The outbreak of clade Ib monkeypox virus (MPXV) continues predominantly in the Democratic Republic of the Congo, Burundi and Uganda, with new travel-related cases identified in previously unaffected countries.
- Recent travel-associated mpox cases highlight the risk of undetected transmission in countries, emphasizing the need for strengthened surveillance and timely reporting to improve global monitoring and prevent international spread.
- The Democratic Republic of the Congo remains the most affected country, experiencing circulation of both clade I MPXV subclades. Despite many of the provinces reporting stable trends in cases, the situation in the country remains concerning with continued high circulation of the virus.
- Burundi and Uganda continue reporting between 100-200 new mpox cases per week, with a plateauing trend, possibly impacted by a decline in surveillance and reporting during the December festive season.
- Since the last update (23 December 2024), Uganda has reported six deaths, bringing the total to 12 deaths among confirmed mpox cases in the country.
- A travel-related case of mpox due to clade Ib MPXV i in Germany (the second importation) led to secondary household transmission.
- Clade Ib MPXV has been detected in three additional countries, Belgium, China and France, directly or indirectly linked to travel to affected countries in Central Africa.
- Kosovo² has reported its first case of mpox. Information on the MPXV clade is not yet available.

[p.18]

5. Access to and delivery of countermeasures

Vaccines

- WHO has continued to provide technical support to accelerate implementation and uptake of mpox vaccination in affected countries in at-risk groups, in support of controlling the surge in mpox cases on the African continent.

- The AAM partners have continued to monitor the progress of the allocation and delivery process to prevent stock expiry and continue to advocate for targeted vaccination in affected hotspots.
- As of 29 December 2024, 87 158 persons had been vaccinated against mpox with the MVA-BN vaccine in the Democratic Republic of the Congo (55 266 persons with the first dose and 31 892 persons with the second dose).
- Efforts are underway to advance delivery of remaining vaccine doses that were allocated during the first allocation round, to finalize the outstanding shipment arrangements and documentation.
- Over 4.83 million vaccine doses are expected to be available in 2025. The vaccine supply includes contributions from multiple nations and organizations, including 1.73 million dose donations of MVA-BN (150 000 doses from the European Union, 696 200 doses from the United States, 876 300 doses procured through UNICEF/Gavi), 50 000 doses of ACAM2000 vaccine from Emergent BioSolutions, as well as a further 3.05 million doses of LC16m8 vaccine from Japan.
- The AAM partners have continued to work together to ensure countries receive guidance to get operational funds for implementation of the national vaccination plans.

.....

Polio – PHEIC

Polio this week – 08 January 2025

Headlines

No new digest content identified.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: one WPV1 case and 13 WPV1-positive environmental samples
- Indonesia: one cVDPV2 case
- Nigeria: three cVDPV2 cases
- United Kingdom (UK): one cVDPV2-positive environmental sample

.....

Public Consultations/Call for Inputs/Call for Papers

Call for inputs for the comprehensive report, incl. new developments, in ensuring access to medicines, vaccines and other health products

Issued by OHCHR

Deadline 20 January 2025

Purpose:

Consultation as per HRC resolution 50/13 and also to inform the comprehensive report on access to medicines, vaccines and other health products

Background

Human Rights Council resolution [50/13](#), requested the Office of the High Commissioner to prepare a comprehensive report, incl. new developments, in ensuring access to medicines, vaccines and other health products and to present it to the Council at its fifty-ninth session in June 2025.

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

WHO & Regional Offices [to 11 Jan 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

[WHO prequalifies diagnostic test to support safer administration of *P. vivax* malaria treatments](#)

Decision reflects updated processes to improve efficiency, access

8 January 2025 *News release*

On 18 December 2024, the World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency which can help to safely deliver WHO-recommended treatments to prevent relapse of *Plasmodium vivax* (*P. vivax*) infection.

The prequalification of this G6PD diagnostic test marks a significant milestone in facilitating safe and effective *P. vivax* malaria treatment, reaffirming WHO's dedication to ensuring equitable access to life-saving health solutions globally. Some 500 000 people die each year from malaria, most of them children.

The prequalification of this test immediately followed the prequalification, in early December, of two new tafenoquine products for anti-relapse treatment of *P. vivax* malaria, and these therapeutics were recommended in updated [WHO malaria guidelines](#) released a few days earlier, in late November.

This package of actions by WHO reflects the organization's recent adoption of synchronized and parallel processes for two key functions: developing recommendations for essential health products and overseeing their prequalification...

.....

WHO Regional Offices

Selected Press Releases, Announcements

[WHO African Region AFRO](#)

:: 02 January 2025


[Chad: protecting children from HIV/AIDS](#)

[WHO Region of the Americas PAHO](#)

:: 6 Jan 2025

[PAHO launches interactive dashboard to monitor avian influenza A\(H5N1\) in the Americas](#)

Washington, DC, January 6, 2025 (PAHO) - The Pan American Health Organization (PAHO) has launched an interactive dashboard to monitor avian influenza A(H5N1) cases in the Americas. This tool is designed to improve access to data on outbreaks of this disease in birds, mammals, and humans, providing key information for public and animal health...



WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

Website not responding at inquiry.

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

:: 9 January 2025

[Vanuatu responds to multiple health challenges following 7.3 magnitude earthquake](#)

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

[Multi-country outbreak of mpox, External situation report #45 - 11 January 2025](#)

Overview

This is the 45th situation report for the multi-country outbreak of mpox, which provides details on the latest epidemiological trends. The outbreak of clade Ib monkeypox virus (MPXV) continues predominantly in the Democratic Republic of the Congo, Burundi and Uganda, with new travel-related cases identified in previously unaffected countries. Recent travel-associated mpox cases highlight the risk of undetected transmission in countries, emphasizing the need for strengthened surveillance and timely reporting to improve global monitoring and prevent international spread.

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

7 January 2025 | Trends of acute respiratory infection, including human metapneumovirus, in the Northern Hemisphere

Situation at a glance

In many countries of the Northern Hemisphere, trends in acute respiratory infections increase at this time of year. These increases are typically caused by seasonal epidemics of respiratory pathogens such as seasonal influenza, respiratory syncytial virus (RSV), and other common respiratory viruses, including human metapneumovirus (hMPV), as well as mycoplasma pneumoniae. Many countries conduct routine surveillance for acute respiratory infections and common respiratory pathogens.

Currently, in some countries in the temperate Northern hemisphere, influenza-like illness (ILI) and/or acute respiratory infection (ARI) rates have increased in recent weeks and are above baseline levels, following usual seasonal trends. Seasonal influenza activity is elevated in many countries in the Northern hemisphere. Where surveillance data is available, trends in RSV detections currently vary by region with decreases reported in most regions except in North America.

Recently, there has been interest in hMPV cases in China including suggestions of hospitals being overwhelmed. hMPV is a common respiratory virus found to circulate in many countries in winter through to spring, although not all countries routinely test and publish data on trends in hMPV. While some cases can be hospitalized with bronchitis or pneumonia, most people infected with hMPV have mild upper respiratory symptoms similar to the common cold and recover after a few days. Based on data published by China, covering the period up to 29 December 2024, acute respiratory infections have increased during recent weeks and detections of seasonal influenza, rhinovirus, RSV, and hMPV, particularly in northern provinces of China have also increased. The observed increase in respiratory pathogen detections is within the range expected for this time of year during the Northern hemisphere winter.

In China, influenza is the most commonly detected respiratory pathogen currently affecting people with acute respiratory infections. WHO is in contact with Chinese health officials and has not received any reports of unusual outbreak patterns. Chinese authorities report that the health care system is not overwhelmed and there have been no emergency declarations or responses triggered. WHO continues to monitor respiratory illnesses at global, regional and country levels through collaborative surveillance systems, and provides updates as needed.

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 100, Nos. 1/2, pp. 1–6 10 January 2025

PDF: <https://iris.who.int/bitstream/handle/10665/380068/WER10001-02-eng-fre.pdf>

:: Cascading skills for monitoring and evaluation of the International Health Regulations (2005) in fragile African countries by training trainers.

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

9 January 2025

Training on influenza data management, analysis and pandemic influenza severity assessment

6 January 2025

Diagnostic target product profiles for trachoma surveillance

3 January 2025

[Developing a model for mass gathering medical care planning: workshop report, Lyon, France, 27-28](#)

.....
.....

USA – HHS, FDA, CDC

HHS

News

[HHS Releases Strategic Plan for the Use of Artificial Intelligence to Enhance and Protect the Health and Well-Being of Americans](#)

January 10, 2025 *News Release*

[HHS awards \\$306 million in Avian Flu monitoring and preparedness funding](#)

January 3, 2025 *News Release*

FDA

Press Announcements

[FDA Roundup: January 10, 2025](#)

On Wednesday, the FDA released a Request For Comments (RFC) soliciting public input on new opportunities and emergent monitoring needs for possible inclusion in the forthcoming National Antimicrobial Resistance Monitoring System (NARMS) 2026-2030 Strategic Plan. The Federal Register notice about the RFC includes instructions for submitting comments, as well as specific questions and requests for information meant to prompt helpful submissions. The agency will be accepting public comments through March 26, 2025.

FDA VRBPAC

Advisory Committee Calendar

No new calendar dates identified.

CDC/ACIP [U.S.] [to 11 Jan 2025]

<http://www.cdc.gov/media/index.html>

Latest News

[U.S. Government Releases First National One Health Plan to Protect People, Animals, and Our Environment from Shared Health Threats](#)

U.S. Government releases first national One Health plan to protect from shared health threats.

Jan 10, 2025

[First H5 Bird Flu Death Reported in United States](#)

A person with severe avian influenza A(H5N1) illness ("H5N1 bird flu") has passed away.

Jan 6, 2025

ACIP Meetings

Next ACIP Meeting

February 26-27, 2025

MMWR Weekly

<https://www.cdc.gov/mmwr/index2024.html>

No new digest content identified.

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

[New EU rules for health technology assessments become effective](#)

Enhanced EU collaboration to allow faster and wider access to innovative health technologies

10 January 2025

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[The first six EU reference laboratories for public health are now operational](#)

9 Jan 2025

[Increase in respiratory infections in China](#)

8 Jan 2025

Surveillance and monitoring

[Communicable disease threats report, 4-10 January 2025, week 2](#)

10 Jan 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 4 - 10 January 2025 and includes updates on respiratory virus epidemiology in the EU/EEA, measles, mpox clades I and II, Middle East respiratory syndrome coronavirus (MERS-CoV), respiratory viral infections in China, and avian influenza A(H5N1).

Surveillance and monitoring

[Monthly measles and rubella monitoring report - November 2024](#)

9 Jan 2025

This report provides an overview of measles and rubella cases reported to ECDC through The European Surveillance System (TESSy).

.....
.....

Africa CDC [to 11 Jan 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

No new digest content identified.

.....

China CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 11 Jan 2025]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 11 Jan 2025]

<http://english.nmpa.gov.cn/>

News

[China deepens comprehensive reform to strengthen drug, medical device regulation](#)

2025-01-06

China has issued a guideline on comprehensively deepening the reform of regulation of drugs and medical devices to promote the high-quality development of the pharmaceutical industry.

[1st stem cell therapy, new HIV drug approved](#)

2025-01-06

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication associated with bone marrow transplant, as well as a novel HIV drug that only requires two shots yearly.

China CDC

[CCDC Weekly Reports: Current Volume \(7\)](#)

2025-01-10 / No. 2 HIV ISSUE

[PDF of this issue](#)

- [Vital Surveillances: Pretreatment HIV Drug Resistance to Integrase Strand Transfer Inhibitors Among Newly Diagnosed HIV Individuals — China, 2018–2023](#)
- [Preplanned Studies: Characteristics and Predictors of Interprovincial Migration Following HIV Diagnosis Among Men Who Have Sex with Men — China, 2016–2022](#)
- [Preplanned Studies: Associations of First-Year Low-Level Viremia with Subsequent Viral Non-Suppression in People Living with HIV on Antiretroviral Therapy — Dehong Dai and Jingpo Autonomous Prefecture, Yunnan Province, China, 2008–2021](#)
- [Preplanned Studies: Accuracy of the Self-Administered Rapid HIV Urine Test in a Real-World Setting and Individual Preferences for HIV Self-Testing — Guangzhou City, Guangdong Province, China, July 2020–February 2021](#)
- [Recollection: Synergizing Digital and Physical Approaches: Experience Summary of the HIV PrEP Promotion Project](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, October 2024*](#)

.....

.....

[Contents \[click to move among sections\]](#)

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

[Organization Announcements](#)

Paul G. Allen Frontiers Group [to 11 Jan 2025]

<https://alleninstitute.org/news-press/>

News

CryoSCAPE: Allen Institute scientists develop 'suspended animation' technique for blood draws that will aid research for underserved populations

01.06.2025

A new approach that keeps blood cells alive in deep freeze promises to expand reach of cutting-edge single-cell technologies to underserved..

BMGF - Gates Foundation [to 11 Jan 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 11 Jan 2025]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 11 Jan 2025]

<https://carb-x.org/>

News

01.09.2025 |

CARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections

CARB-X will award Peptilogics \$3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.

01.07.2025 |

CARB-X funds Clarametix Biosciences to develop anti-biofilm vaccine

CARB-X will award Clarametix Biosciences US\$2.6 million to develop a Lead Optimization workplan to support its novel broad-spectrum, anti-biofilm vaccine program.

CEPI – Coalition for Epidemic Preparedness Innovations [to 11 Jan 2025]

<http://cepi.net/>

CEPI News

News

CEPI and Micron Biomedical accelerate needle-free vaccines against Disease X

The research will advance development of Micron's small "button" technology that is applied to the skin and can deliver a vaccine when pushed.

7 Jan 2025

News

CEPI and the US DFC join forces to tackle future pandemic threats

5 Jan 2025

CEPI and the U.S. International Development Finance Corporation (DFC) have announced a new intention to collaborate and advance global health security by aligning their discussions and investments in global vaccine initiatives, including exploring sustainable pandemic financing tools and supporting localised vaccine production efforts...

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 11 Jan 2025]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 11 Jan 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 11 Jan 2025]

<https://dndi.org/press/press-releases/>

Press Releases

No new digest content identified.

Duke Global Health Innovation Center [to 11 Jan 2025]

<https://dukeghic.org/>

News

[Issue 5: 10 January 2025 | Mpox: Transparency and Accountability for the Global Response](#)

January 10, 2025

EDCTP [to 11 Jan 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

No new digest content identified.

Emory Vaccine Center [to 11 Jan 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 11 Jan 2025]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Fondation Merieux [to 11 Jan 2025]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 11 Jan 2025]

<https://www.gavi.org/>

Press Releases

No new digest content identified.

GE2P2 Global Foundation [to 11 Jan 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – January 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 11 Dec 2024 – Issue 26](#)

GHIT Fund [to 11 Jan 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 11 Jan 2025]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 11 Jan 2025]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 11 Jan 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 11 Jan 2025]

<https://www.hhmi.org/news>

Press Room

[HHMI Names the 2024 Hanna Gray Fellows](#)

The cohort includes early career scientists working in research areas ranging from treatment-resistant cancers to how animals evolved to live on land. The HHMI Hanna H. Gray Fellows Program provides each fellow with up to \$1.5 million in support over the span of up to eight years.
January 08, 2025

Human Immunome Project [nee Human Vaccines Project] [to 11 Jan 2025]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 11 Jan 2025]

<https://www.iavi.org/>

Press Releases

No new digest content identified.

INSERM [to 11 Jan 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 11 Jan 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 11 Jan 2025]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

Article 10-01-2025

[Frequently asked questions on the ICRC's work in Israel and the occupied territories](#)

Article 04-01-2025

[Syria Operational Update: ICRC work in Syria \(27 November - 18 December 2024\)](#)

News release 04-01-2025

[Lebanon: ICRC president urges renewal of ceasefire and sustained humanitarian assistance to help civilians rebuild](#)

IFFIm

<http://www.iffim.org/>
Press Releases/Announcements
No new digest content identified.

IFRC [to 11 Jan 2025]
<http://media.ifrc.org/ifrc/news/press-releases/>
Press Releases [Selected]
No new digest content identified.

Institut Pasteur [to 11 Jan 2025]
<https://www.pasteur.fr/en/press-area>
Press Documents
No new digest content identified.

ISC / International Science Council [to 11 Jan 2025]
<https://council.science/current/>
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Latest Updates
No new digest content identified.

International Union of Immunological Societies (IUIS)
<https://iuis.org/>
News/Events [Selected]
No new digest content identified.

IVAC [to 11 Jan 2025]
<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>
Updates; Events
No new digest content identified.

IVI [to 11 Jan 2025]
<http://www.ivi.int/>
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 11 Jan 2025]
<https://centerforhealthsecurity.org/newsroom>
Center News [Selected]
January 7, 2025:
[Center for Health Security announces fellows accepted to Emerging Leaders in Biosecurity Initiative class of 2025](#)

MSF/Médecins Sans Frontières [to 11 Jan 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

Conflict in Sudan

MSF denounces violent attacks leading to suspension of activities at key Khartoum hospital

Press Release 10 Jan 2025

Gaza-Israel war

Newborns and other patients at risk as Nasser hospital in Gaza runs out of fuel, MSF warns

Press Release 8 Jan 2025

Social violence and exclusion

Access to healthcare is seriously compromised in H2 area of Hebron

Press Release 8 Jan 2025

Gaza-Israel war

Strikes, raids and incursions: Over a year of relentless attacks on healthcare in Palestine

Project Update 7 Jan 2025

National Academy of Medicine - USA [to 11 Jan 2025]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 11 Jan 2025]

<https://www.nationalacademies.org/newsroom>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 11 Jan 2025]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 11 Jan 2025]

<http://www.nih.gov/>

News Releases

Friday, January 3, 2025

NIH researchers discover novel class of anti-malaria antibodies

New antibodies could lead to next generation of interventions against malaria.

PATH [to 11 Jan 2025]

<https://www.path.org/media-center/>

Newsroom

No new digest content identified.

Sabin Vaccine Institute [to 11 Jan 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 11 Jan 2025]

<http://www.unaids.org/en>

News, Stories, Updates

Feature story

Promoting positive masculinity to end gender-based violence in Armenia

09 January 2025

UNICEF [to 11 Jan 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 08 January 2025

New year brings little new hope for children in Gaza, with at least 74 children reportedly killed in first week of 2025

EAST JERUSALEM/AMMAN/NEW YORK, 8 January 2025 – At least 74 children have reportedly been killed in relentless violence in the Gaza Strip in just the first seven days of 2025. Children have reportedly been killed in several mass casualty events, including nighttime attacks in Gaza City, Khan Younis, and Al Mawasi...

Unitaid [to 11 Jan 2025]

<https://unitaid.org/>

Featured News

New vector control tool effectively reduces malaria transmission in major clinical trial

[Undated]

Unitaid and the University of Notre Dame announced that an innovative vector control tool for malaria called a spatial repellent showed a significant impact on reducing malaria infections in a study published in *The Lancet* today.

The spatial repellent product, Mosquito Shield™, used alongside insecticide-treated nets, reduced first-time and overall malaria infections by one-third (33.4% and 32.1%, respectively), compared to the placebo product...

Vaccine Equity Cooperative [nee Initiative] [to 11 Jan 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative (Sabin) [to 11 Jan 2025]

<https://www.vaccineacceptance.org/>

No new digest content identified.

Vaccine Confidence Project [to 11 Jan 2025]

<http://www.vaccineconfidence.org/>
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 11 Jan 2025]
<http://www.chop.edu/centers-programs/vaccine-education-center>
News
No new digest content identified.

Wellcome Trust [to 11 Jan 2025]
<https://wellcome.org/news/all>
News. Opinion, Reports
News

Announcing three new members of Wellcome’s Executive Committee

9 January 2025

Professor Rachel McKendry has been appointed as Executive Director of Discovery, Professor Charlotte Watts the Executive Director of Solutions, and Maggy Chan as Wellcome’s Chief Operating Officer (COO).

The Wistar Institute [to 11 Jan 2025]
<https://www.wistar.org/news/press-releases>
Press Releases
No new digest content identified.

World Bank [to 11 Jan 2025]
<http://www.worldbank.org/en/news/all>
All News [Selected]
No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 11 Jan 2025]
<https://www.wfpha.org/>
Blog, Events
No new digest content identified.

World Medical Association [WMA] [to 11 Jan 2025]
<https://www.wma.net/news-press/press-releases/>
Press Releases
No new digest content identified.

World Organisation for Animal Health [OIE] [to 11 Jan 2025]
<https://www.oie.int/>
Press Releases, Statements
No new digest content identified.

.....

.....

ARM [Alliance for Regenerative Medicine] [to 11 Jan 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 11 Jan 2025]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 11 Jan 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 11 Jan 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 11 Jan 2025]

<https://ifpma.org/>

News, Statements [Selected]

Expert insights

[How lifelong vaccination can tackle the challenges of an ageing world](#)

7 January 2025

Alongside climate change and rapid technological acceleration, demographic change is often [cited](#) as one of the biggest challenges facing the globe today.

Ensuring there is equitable access to innovative health solutions within this context of a rapidly ageing world has therefore never been more urgent. Whilst childhood vaccination programs have provided a strong foundation for global health for decades, it is critical that our focus expands to include a comprehensive, life-course immunization strategy.

International Alliance of Patients' Organizations – IAPO [to 11 Jan 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 11 Jan 2025]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....

.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - *No new digest announcements identified*

Bavarian Nordic

Latest News *No new digest content identified.*

Bharat Biotech

Press Releases - *No new digest announcements identified*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified*

Biological E

News - *No new digest announcements identified*

BioNTech

Press Releases - *No new digest announcements identified.*

Boehringer

Press Releases - *No new digest announcements identified.*

CanSinoBIO

News - *Website not responding at inquiry*

CIGB

Latest News - *No new digest announcements identified.*

Cinnagen

Recent News - *No new digest announcements identified.*

Clover Biopharmaceuticals – China

News - *No new digest announcements identified.*

Curevac

News - *No new digest announcements identified.*

Gamaleya National Center/Sputnik

Latest News and Events - *No new digest announcements identified [Last: 09 Nov 2020]*

<https://sputnikvaccine.com/> - *No new digest announcements identified [Last: 31 Aug 2022]*

GSK

Press releases for media

10 January 2025

GSK's Shingrix new prefilled syringe presentation accepted for review by US FDA

:: If approved, the new presentation will offer a convenient administration option to healthcare professionals

:: Over 90 million doses of GSK's shingles vaccine have been distributed in the US since 2011

:: An FDA decision on the application is expected by 20 June 2025

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases

Neuroscience

Johnson & Johnson's Posinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease

January 8, 2025

United States

Merck

News releases

Merck's GARDASIL® Receives Expanded Approval for Males in China

January 106, 2025

GARDASIL is the first HPV vaccine approved for the prevention of certain HPV-related cancers and diseases in Chinese males

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the National Medical Products Administration (NMPA) of China approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for use in males 9-26 years of age to help prevent certain HPV-related cancers and diseases.

The approval makes GARDASIL the first HPV vaccine approved for use in males in China. GARDASIL is now indicated in China to prevent anal cancers caused by HPV Types 16 and 18, genital warts (condyloma acuminata) caused by HPV Types 6 and 11, and the following precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, and 18: grade 1, grade 2, and grade 3 anal intraepithelial neoplasia (AIN).

"The approval of GARDASIL for use in males 9-26 years old in China is a significant step forward in advancing public health," said Joseph Romanelli, president, Human Health International, Merck. "Since first approval, our HPV vaccines have helped protect over 50 million females in China from certain HPV-related cancers and diseases. With this expanded approval, we look forward to helping protect this new population of Chinese males from certain HPV-related cancers and diseases."

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

[Press Releases](#) - No new digest announcements identified.

Pfizer

[Recent Press Releases](#) - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified.

Serum Institute

[News & Announcements](#) - No new digest announcements identified.

Sinopharm/WIBPBIBP

[News](#)

[Africa CDC delegation visits CNBG](#)

Updated:2025-01-08

A delegation from the Africa Centres for Disease Control and Prevention (Africa CDC) visited Beijing Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group Company Limited (CNBG) under China National Pharmaceutical Group Co Ltd (Sinopharm), on Dec 17...The two sides aim to facilitate localized vaccine production in Africa, enhancing the accessibility and affordability of medical products and contributing to the global fight against infectious diseases.

Sinovac

[Press Releases](#) - No new digest announcements identified.

SK Biosciences

[Press Releases](#) - No new digest announcements identified.

Takeda

[Newsroom](#) - No new digest announcements identified.

Valneva

[Press Releases](#) - No new digest announcements identified.

Vector State Research Centre of Virology and Biotechnology

[Home](#) - [Website not responding [404 error]]

WestVac Biopharma

[Media](#) - Website not responding at inquiry.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) [No News/Announcements page identified]

.....
.....

[Contents](#) [click to move among sections]

:: [Milestones, Perspectives](#)
:: [WHO](#)
:: [Organization Announcements](#)
:: [Journal Watch](#)
:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 1: E1-65 Jan 2025

<https://journalofethics.ama-assn.org/issue/epidemiology-and-clinical-practice>

Epidemiology and Clinical Practice

Epidemiological research guides health service delivery by informing and transforming clinical guidelines. Reciprocally, how clinicians document information from patients or their loved ones also determines the quality of data epidemiologists use in research. Additionally, some patients' health needs and some communities' health interests are not well captured in observational studies and clinical trials, especially when patient-subjects are lost to follow-up. Attrition of patient-subjects who are uninsured, underinsured, experience transportation or food insecurity, work multiple jobs, or live with complex chronic illnesses or disabilities, for example, creates data capture gaps, which can result in an evidence base that is incomplete and clinical guidelines that are inapt, inequitable, or simply do not apply to a full range of patients. This theme issue investigates these and other complexities of epidemiological data sourcing and the ethics of practice guideline formation.

American Journal of Human Genetics

Jan 02, 2025 Volume 112 Issue 1 p1-198

<https://www.cell.com/ajhg/current>

This month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Loss-of-function variants are typically considered in terms of gene-specific, pathway-dependent effects. An altered protein is produced, affecting the protein-specific pathway or a related phenotype. However, characterizing the gene-specific, pathway-dependent effects alone does not always explain the phenotypic variability observed between individuals with the same mutation or predict disease trajectory. In this issue, Shovlin and Aldred present a parallel paradigm for loss-of-function variants based on proteostasis, the process of maintaining a healthy balance of proteins within a cell.

American Journal of Infection Control

January 2025 Volume 53 Issue 1 p1-174

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

January 2025 Volume 68 Issue 1 p1-216

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

January 2025 115(1)

<http://ajph.aphapublications.org/toc/ajph/current>

Displacements to Escape Natural Disasters In The United States

The January issue of *AJPH* focuses on the increasing prevalence of natural disaster-induced displacements within the United States. Featured articles explore disparities in the impact of these displacements and examine their prevalence and correlates. Other articles in this issue address naloxone distribution programs, urban reforestation efforts in Manhattan, the role of health monitoring data in relation to immigration and citizenship, and the use of long-acting reversible contraception.

American Journal of Tropical Medicine and Hygiene

Volume 111 (2024): Issue 6 (Dec 2024)

<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.111.issue-6.xml>

Articles

[Reviewed earlier]

Annals of Internal Medicine

December 2024 Volume 177, Issue 12

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 337 December 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/337/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 11 Jan 2025)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 11 Jan 2025)
[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 11 Jan 2025)

[Association between contextual factors and vaccine coverage against human papillomavirus in adolescents in the state of Minas Gerais, Brazil: global spatial regressions](#)

This study aimed to identify the associations between socioeconomic factors, the social environment, and human papillomavirus (HPV) vaccine coverage among adolescents in the state of Minas Gerais (MG), Brazil....

Authors: Bianca Maria Oliveira Luisaro, Thales Philipe Rodrigues da Silva, Josianne Dias Gusmão, Marcela Lencine Ferraz, Luciana Maiara Diogo Nascimento, Larissa Pereira Gomes and Fernanda Penido Matozinhos

Citation: BMC Infectious Diseases 2025 25:34

Content type: Research Published on: 7 January 2025

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 11 Jan 2025)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 11 Jan 2025)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 11 Jan 2025)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 11 Jan 2025)

[Global, regional, and national incidence and mortality for enteric infections from 1990 to 2019](#)

Enteric infections are among the most common infectious diseases. The aim of this article was to track the global trends in morbidity and mortality from enteric infections in 204 countries or territories from ...

...

Authors: Bo Wang, Dongwei Chen, Hua Chen, Wei Wu, Kaiyi Cheng, Yixiu Tao, Ling Zhang, Ce Liu, Ding Ou, Mingxiu Zhang, Xianmei Tang, Shouli Wang, Guangzhu Wang and Bin Luo

Citation: BMC Public Health 2025 25:100

Content type: Research Published on: 8 January 2025

[Beliefs and attitudes of Syrian refugee mothers in Lebanon regarding children vaccination: a cross-sectional study](#)

Vaccines have contributed to the disappearance of various diseases, and almost eradicated others across the world. Studies have shown that in Lebanon a profoundly small percentage of Syrian refugee children we...

Authors: Issam Shaarani, Sleiman Khadem, Marwa Obeid, Behnaz Saadieh, Aya Serhal, Karim Zakkour, Sara Mohammad, Hussein Berjaoui and Nour Izmirli

Citation: *BMC Public Health* 2025 25:99

Content type: Research Published on: 8 January 2025

Socioeconomic disparities in influenza vaccination uptake: impact of the COVID-19 pandemic in South Korea

This study aimed to investigate the sociodemographic and behavioral factors related to increased influenza vaccination uptake during the COVID-19 pandemic in South Korea, particularly among adults not eligible...

Authors: Muhan Yeo, Jeongmin Seo and Juwon Lim

Citation: *BMC Public Health* 2025 25:42

Content type: Research Published on: 6 January 2025

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 11 Jan 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

December 2024 - Volume 29 - 6

<https://ebm.bmj.com/content/29/6>

[Reviewed earlier]

BMJ Global Health

December 2024 - Volume 9 - 12

<https://gh.bmj.com/content/9/12>

[Reviewed earlier]

Bulletin of the World Health Organization

2024 Dec 1; 102(12)

<https://www.who.int/publications/journals/bulletin/>

In this month's Bulletin

This month's theme issue on sexual health is introduced in an editorial by Manjulaa Narasimhan and Pascale Allotey (842). In related editorials, Sagri Singh et al. (843) advocate for improved sexual health and well-being and Nicaise Ndembi et al. (844) explain how mpox poses a new threat. Etienne V Langlois et al. (845) present a critical pathway for the reduction of maternal newborn and child mortality.

Gary Humphrey (848–849) reports on efforts to communicate effectively about mpox transmission while avoiding stigmatization. Haven Ley talks to Humphreys (850–851) about Pivotal Ventures, established to further social progress and address women's sexual health and reproductive rights.

Cell

Dec 26, 2024 Volume 187 Issue 26 p7351-7656

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

Child Care, Health and Development

Volume 51, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 117, Issue 1 Pages: 1-310 January 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[New issue; No digest content identified]

Clinical Therapeutics

January 2025 Volume 47 Issue 1 p1-114

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

Clinical Trials

Volume 21 Issue 6, December 2024

<https://journals.sagepub.com/toc/ctja/21/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 11 Jan 2025]

[No new digest content identified]

Contemporary Clinical Trials

Volume 148 January 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/147/suppl/C>

[New issue; No digest content identified]

The CRISPR Journal

Volume 7, Issue 6 / December 2024

<https://www.liebertpub.com/toc/crispr/7/6>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 12 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

February 2025 - Volume 38 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

STD

Progress towards effective vaccines for *Chlamydia trachomatis*

Collar, Amanda L.; Fietze, Kathryn M.

Current Opinion in Infectious Diseases. 38(1):54-59, February 2025.

Vaccine hesitancy and other challenges to sexually transmitted infection vaccine acceptance

Footman, Alison; Griner, Stacey B.

Current Opinion in Infectious Diseases. 38(1):60-64, February 2025.

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 11 Jan 2025]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 4 Pages: 263-342 December 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

Development Policy Review

Volume 43, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 49, Issue 1 January 2025
<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>
[Reviewed earlier]

EMBO Reports

Volume 26 Issue 1 10 January 2025

Opinion 20 November 2024

[Soul Men and Women—what must science do to regain public trust?](#)

Arthur Caplan

To meet the growing deluge of misinformation and distortion of scientific facts, science desperately needs a PR makeover.

Emerging Infectious Diseases

Volume 31, Number 1—January 2025

<http://wwwnc.cdc.gov/eid/>

Perspective

[Global Health's Evolution and Search for Identity](#) [PDF - 325 KB - 7 pages]

K. M. De Cock

Despite earlier attempts to define global health, the discipline's boundaries are unclear, its priorities defined more by funding from high-income countries from the Global North than by global health trends. Governance and resource allocation are challenged by movements such as decolonizing global health. Inherent contradictions within global health derive from its historical evolution from tropical medicine and international health, as well as recent trends in infectious diseases. Demographic, socioeconomic, and epidemiologic transitions, including the rise in noncommunicable diseases, have eroded the concept of a binary world of developed and developing countries. Competitive tension has emerged between aspirations for global health security and health equity. Dominant principles should focus on vulnerable populations, transnational challenges such as migration and climate change, appropriate prevention and care, and epidemic preparedness and response capacity. As the 2030 target date for the United Nations Sustainable Development Goals approaches, reconceptualization of global health is required, or the discipline risks losing identity and relevance.

Synopses

[The Rise of Mpox in a Post-Smallpox World](#) [PDF - 263 KB - 5 pages]

J. H. McQuiston et al.

Abstract

Reports of mpox are rising in Africa where the disease is endemic and in new countries where the disease has not been previously seen. The 2022 global outbreak of clade II mpox and an ongoing outbreak of the more lethal clade I mpox highlight the pandemic potential for monkeypox virus. Waning population immunity after the cessation of routine immunization for smallpox plays a key role in the changing epidemiologic patterns of mpox. Sustained human-to-human transmission of mpox is occurring widely in the context of insufficient population immunity, fueling genetic mutations that affect the accuracy of some diagnostic tests and that could lead to changing virulence. Additional research should address complex challenges for control of mpox, including improved diagnostics and medical countermeasures. The availability of vaccines should be expanded not only for outbreak response but also for broader routine use for persons in mpox-endemic countries.

Online Reports

[Research and Development of Medical Countermeasures for Emerging Infectious Diseases, China, 1990–2022](#) [PDF - 1.04 MB - 8 pages]

J. Ma et al.

Abstract

Since the severe acute respiratory syndrome outbreak in 2003, China has invested substantial efforts in promoting scientific and technological advances for medical countermeasures against high-threat pathogens. The examination of China's landscape identifies progress and gaps in research and development (R&D) and also highlights management and regulatory issues that should be of concern to other countries. Our study examined the current state of R&D of medical countermeasures in China during 1990–2022. The findings showed a robust and diversified pipeline responding quickly to disease outbreaks and policy changes. However, proactive and highly innovative candidates are limited, and a large proportion of vaccines and drugs stagnate at the early development stage. A paradigm shift involving a preemptive R&D agenda and persistent investment, innovative technology development, and accelerated research translation is urgently needed to prepare for the next pandemic.

Epidemics

Volume 49 December 2024

<https://www.sciencedirect.com/journal/epidemics/vol/49/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

Original Paper

The effect of SARS-CoV-2 infection and COVID-19 vaccination during pregnancy on neonatal outcomes

Anne J. Huiberts, Ilse J. Oosting, Hester E. de Melker, Janneke H. H. M. van de Wijgert, Diederick E. Grobbee, Susan van den Hof, Mirjam J. Knol

Published online by Cambridge University Press:

16 December 2024, e5

Ethics & Human Research

Volume 46, Issue 6 Pages: 1-35 November–December 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Data monitoring committee insights / Ethics reviews and AI tools

[Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 2 - Summer 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 5, October 2024

<https://academic.oup.com/eurpub/issue/34/5>

[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

Article

[Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia](#)

[Nadine Al Akoury](#), [Julia Spinardi](#), [Hammam Haridy](#), [Mostafa Moussa](#), [Mohammed Attia Elshabrawi](#), [Carlos Fernando Mendoza](#), [Jingyan Yang](#), [Josie Dodd](#), [Moe H. Kyaw](#) & [Benjamin Yarnoff](#)

Pages: 27-36

Published online: 17 Dec 2024

Article

[Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States](#)

[Salini Mohanty](#), [Jui-Hua Tsai](#), [Ning Ning](#), [Ana Martinez](#), [Rishi P. Verma](#), [Bianca Chun](#), [Kelly D. Johnson](#), [Nicole Cossrow](#), [M.Doyinsola Bailey](#), [Thomas Weiss](#), [Elmira Flem](#) & [Jordana K. Schmier](#)

Pages: 45-52

Published online: 19 Dec 2024

Article

[Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018–2024: a database study](#)

[Yi Zheng](#), [Dong Wang](#), [Ya-Ting Chen](#), [Kunal Saxena](#), [Goran Bencina](#) & [Amanda L. Eiden](#)

Pages: 53-66

Published online: 22 Dec 2024

Foreign Affairs

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>

Special Section

Will Trump Change the World?

Forum for Development Studies

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 11 Jan 2025]

Original Research Published on 10 Jan 2025

[Comparison of good review practices of seven countries participating in the ECOWAS medicines regulatory harmonisation initiative: identifying opportunities for improvement](#)

[Mercy Owusu-Asante](#), et al

Frontiers in Medicine doi 10.3389/fmed.2024.1520892

Systematic Review Published on 08 Jan 2025

Artificial intelligence in healthcare: transforming patient safety with intelligent systems—A systematic review

Francesco De Micco, et al.

Frontiers in Medicine doi 10.3389/fmed.2024.1522554

Perspective Published on 07 Jan 2025

Gaps in the ethical governance of pharmaceutical clinical trials in Europe

Rosemarie D. L. C. Bernabe. Shereen A. Dawkins-Cox, Christine C. Gispen-de Wied

Frontiers in Medicine doi 10.3389/fmed.2024.1507021

Gene Therapy – Nature

Volume 31 Issue 11-12, November 2024

<https://www.nature.com/gt/volumes/31/issues/11-12>

[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 1 January 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/1>

Research article Open access

The Clinical Genome Resource (ClinGen): Advancing genomic knowledge through global curation

Erica F. Andersen, Danielle R. Azzariti, Larry Babb, Jonathan S. Berg, ... Joannella Morales

Article 101228

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 11 Jan 2025]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 11 Jan 2025]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 11 Jan 2025]

[No new digest content identified]

Health and Human Rights

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

Special Section: Distress Migration and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 3 - July 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 10, December 2024

<https://academic.oup.com/heapol/issue/39/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 11 Jan 2025]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 23-24 / December 2024

<https://www.liebertpub.com/toc/hum/35/23-24>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[Space for engagement: rethinking the humanitarian role](#)

January 9, 2025

Alasdair Gordon-Gibson

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Dec 10, 2024 Volume 57 Issue 1 2p2705-2958

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 11 Jan 2025]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 11 Jan 2025]

[No new digest content identified]

International Health

Volume 17, Issue 1, January 2025

<https://academic.oup.com/inthealth/issue/17/1>

[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 2 (Dec 2024)

<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>

[New issue; No digest content identified]

International Journal of Community Medicine and Public Health

Vol. 12 No. 1 (2025): January 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/120>

<https://academic.oup.com/ije/issue/53/6>

[Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 6, December 2024

<https://academic.oup.com/ije/issue/53/6>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 4 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>

Table of contents

[Reviewed earlier]

JAMA

January 7, 2025, Vol 333, No. 1, Pages 5-96

<https://jamanetwork.com/journals/jama/currentissue>

Ethics and Medical Research

This JAMA Special Communication presents a series of articles and commentaries focused on the 2024 revision of the World Medical Association's Declaration of Helsinki, a set of principles to guide the ethical treatment of participants in medical research.

[Vaccines and Global Health covered this content earlier when it was initially released in JAMA's online-first section]

JAMA Health Forum

January 2025, Vol 6, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

December 2024, Vol 178, No. 12, Pages 1237-1379

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

December 2024 - Volume 22 - Issue 12

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

January 2025 Volume 76 Issue 1 p1-172

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 81 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 6 December 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 11 (2024)

<https://www.cmro.in/index.php/jcmro/issue/view/89>

[Reviewed earlier]

Journal of Development Economics

Volume 172 January 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/172/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

December 2024 - Volume 78 - 12

<https://jech.bmj.com/content/78/12>

[New issue; No digest content identified]

Journal of Evidence-Based Medicine

Volume 17, Issue 4 Pages: 689-873 December 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 3 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

Special Issue: 20th Anniversary Forum

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 4, November 2024

<https://muse.jhu.edu/issue/53739>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 5 October 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 8 Pages: 1-3156 November 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

January 2025 - Volume 51 - 1

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 275 December 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/275/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

January/February 2025 - Volume 31 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 4, December 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-4>

[Reviewed earlier]

Journal of the Royal Society – Interface

December 2024 Volume 21 Issue 221
<https://royalsocietypublishing.org/toc/rsif/current>
[Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 8, December 2024
<https://academic.oup.com/jtm/issue>
[Reviewed earlier]

Journal of Virology

Volume 98 • Number 11 • November 2024
<http://jvi.asm.org/content/current>
[Reviewed earlier]

The Lancet

Jan 11, 2025 Volume 405 Number 10473 p97-172
<https://www.thelancet.com/journals/lancet/issue/current>
Editorial

[Infectious diseases in 2025: a year for courage and conviction](#)

The Lancet

Articles

[Effect of a spatial repellent on malaria incidence in an area of western Kenya characterised by high malaria transmission, insecticide resistance, and universal coverage of insecticide treated nets \(part of the AEGIS Consortium\): a cluster-randomised, controlled trial](#)

Eric O Ochomo, et al.

The Lancet Child & Adolescent Health

Jan 2025 Volume 9 Number 1 p1-76
<https://www.thelancet.com/journals/lanchi/issue/current>
Editorial

[Child-first societies are safe societies for all](#)

The Lancet Child & Adolescent Health

Personal View

[Creating child-inclusive societies](#)

Helen Skouteris, Michael Marmot, Sharon Bessell

Lancet Digital Health

Jan 2025 Volume 7 Number 1 e1-e102
<https://www.thelancet.com/journals/landig/issue/current>
Review

[Tackling algorithmic bias and promoting transparency in health datasets: the STANDING Together consensus recommendations](#)

Joseph E Alderman, et al.

Summary

Without careful dissection of the ways in which biases can be encoded into artificial intelligence (AI) health technologies, there is a risk of perpetuating existing health inequalities at scale. One major source of bias is the data that underpins such technologies. The STANDING Together recommendations aim to encourage transparency regarding limitations of health datasets and proactive evaluation of their effect across population groups. Draft recommendation items were informed by a systematic review and stakeholder survey. The recommendations were developed using a Delphi approach, supplemented by a public consultation and international interview study. Overall, more than 350 representatives from 58 countries provided input into this initiative. 194 Delphi participants from 25 countries voted and provided comments on 32 candidate items across three electronic survey rounds and one in-person consensus meeting. The 29 STANDING Together consensus recommendations are presented here in two parts. Recommendations for Documentation of Health Datasets provide guidance for dataset curators to enable transparency around data composition and limitations. Recommendations for Use of Health Datasets aim to enable identification and mitigation of algorithmic biases that might exacerbate health inequalities. These recommendations are intended to prompt proactive inquiry rather than acting as a checklist. We hope to raise awareness that no dataset is free of limitations, so transparent communication of data limitations should be perceived as valuable, and absence of this information as a limitation. We hope that adoption of the STANDING Together recommendations by stakeholders across the AI health technology lifecycle will enable everyone in society to benefit from technologies which are safe and effective.

Lancet Global Health

Jan 2025 Volume 13 Number 1 e1-e171

<https://www.thelancet.com/journals/langlo/issue/current>

Comment

Monitoring essential medicines access—unfinished business

Andrew Lofts Gray, Fatima Suleman

Articles

Prices, availability, and affordability of adult medicines in 54 low-income and middle-income countries: evidence based on a secondary analysis

Lachlan Oldfield, et al.

Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda

Eve Nakabembe,

Lancet Infectious Diseases

Jan 2025 Volume 25 Number 1 p1-134, e1-e59

<https://www.thelancet.com/journals/laninf/issue/current>

Editorial

Reflecting on lessons from the 2014–16 Ebola virus outbreak

The Lancet Infectious Diseases

Articles

Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial

Denise Hsu, et al.

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents

Vera Buerger, et al.

Estimates of the burden of human rabies deaths and animal bites in India, 2022–23: a community-based cross-sectional survey and probability decision-tree modelling study

Jeromie Wesley Vivian Thangaraj, et al. for the Human Rabies Study Collaborators

Review

Optimising vaccine immunogenicity in ageing populations: key strategies

Guangzhen Jiang, et al.

Antimicrobial resistance among refugees and asylum seekers: a global systematic review and meta-analysis

Elizabeth D Hermsen, et al.

Personal View

A pox on all our houses: a missing component in the global mpox response is equity

Eddy Jonas, et al.

Lancet Public Health

Jan 2025 Volume 10 Number 1 e1-e70

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

Lancet Respiratory Medicine

Jan 2025 Volume 13 Number 1 p1-100, e1-e8

<https://www.thelancet.com/journals/lanres/issue/current>

[New issue; No digest content identified]

Maternal and Child Health Journal

Volume 28, Issue 12 December 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 1, January 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 4 Pages: 823-1031 December 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Jan 08, 2025 Volume 33 Issue 1 p1-422

<https://www.cell.com/molecular-therapy/current>

Editorial

miRNA discovery to therapy: The field is sufficiently mature to assess the value of miRNA-based therapeutics

Andrew H. Baker, Mauro Giacca, Thomas Thum

It was outstanding for the entire field of non-coding RNA research and related disciplines that the 2024 Nobel Prize in Physiology and Medicine was awarded for the discovery of microRNA (miRNA).^{1,2} The contribution of the Nobel laureates' work and that of subsequent researchers in the field in the following 2 decades of research have studied extensively the canonical function of miRNAs as an essential regulation of cell function in both health and disease. In addition to their role in post-transcriptional regulation, miRNAs are relatively low in number (a couple of thousand in humans) and are generally well conserved across species.

Opinion

When promising therapies are out of reach: Ethical responsibilities of stakeholders in gene therapy trials for rare disorders

Rami M. Major, Zollie Yavarow

When a gene therapy enters the clinic, a nuanced conversation must be conducted with patients who will ultimately decide whether or not to enroll in a clinical trial. A thin line exists between pitching the prospect of a therapeutic benefit to patients and emphasizing the "trial" aspect of a therapy itself. But what does it mean to create a gene therapy that is a success or a failure? An initially promising gene therapy for giant axonal neuropathy was dropped by Taysha Gene Therapies after the FDA recommended a double-blind, placebo-controlled trial with extensive long-term follow-up to demonstrate efficacy.

Nature

Volume 637 Issue 8045, 9 January 2025

<https://www.nature.com/nature/volumes/637/issues/8045>

Editorial 08 Jan 2025

We need to talk about human genome editing

In a few decades, gene-editing technologies could reduce the likelihood of common human diseases. Societies must use this time to prepare for their arrival.

NEWS AND VIEWS 08 January 2025

Human embryo editing against disease is unsafe and unproven — despite rosy predictions

Mathematical modelling suggests that it is theoretically possible to reduce risk of common diseases using heritable genome editing. Scientists argue that the technology involves considerable risk and uncertain benefits.

By Shai Carmi, Henry T. Greely & Kevin J. Mitchell

The possibility of editing the genomes of human embryos has been widely discussed, particularly since the discovery of the CRISPR–Cas9 gene-editing tool. The revelation in late 2018 that a Chinese scientist, He Jiankui, had edited embryos that became living babies created a huge wave of controversy¹. Writing in *Nature*, Visscher *et al.*² describe a mathematical model that argues that just a handful of edits could reduce the risk of various disorders dramatically — in a theoretical scenario in which heritable, large-scale genome editing is feasible and safe. Although the authors' claims are logical and thought-provoking, their model relies on several speculative assumptions and glosses over unknown, but predictable, serious risks. Given the broad interest in this topic, the work will probably be

discussed widely and might ultimately affect policy. It raises both scientific and ethical issues, which we discuss here.

Analysis Open access Published: 08 January 2025

[Heritable polygenic editing: the next frontier in genomic medicine?](#)

Peter M. Visscher, Christopher Gyngell, Loic Yengo & Julian Savulescu

Abstract

Polygenic genome editing in human embryos and germ cells is predicted to become feasible in the next three decades. Several recent books and academic papers have outlined the ethical concerns raised by germline genome editing and the opportunities that it may present^{1,2,3}. To date, no attempts have been made to predict the consequences of altering specific variants associated with polygenic diseases. In this Analysis, we show that polygenic genome editing could theoretically yield extreme reductions in disease susceptibility. For example, editing a relatively small number of genomic variants could make a substantial difference to an individual's risk of developing coronary artery disease, Alzheimer's disease, major depressive disorder, diabetes and schizophrenia. Similarly, large changes in risk factors, such as low-density lipoprotein cholesterol and blood pressure, could, in theory, be achieved by polygenic editing. Although heritable polygenic editing (HPE) is still speculative, we completed calculations to discuss the underlying ethical issues. Our modelling demonstrates how the putatively positive consequences of gene editing at an individual level may deepen health inequalities. Further, as single or multiple gene variants can increase the risk of some diseases while decreasing that of others, HPE raises ethical challenges related to pleiotropy and genetic diversity. We conclude by arguing for a collectivist perspective on the ethical issues raised by HPE, which accounts for its effects on individuals, their families, communities and society⁴.

Perspective 24 Sept 2024

[The global H5N1 influenza panzootic in mammals](#)

This Perspective reviews the molecular and ecological factors that have driven the expansion in geographical distribution and host species range of H5N1 avian influenza viruses, leading to the current panzootic.

Thomas P. Peacock, Louise Moncla, Martha I. Nelson

Nature Biotechnology

Volume 42 Issue 12, December 2024

<https://www.nature.com/nbt/volumes/42/issues/12>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 11 Jan 2025)

[Reviewed earlier]

Nature Genetics

Volume 56 Issue 12, December 2024

<https://www.nature.com/ng/volumes/56/issues/12>

[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 12, December 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/12>

Correspondence 21 Oct 2024

[We need to understand the effect of narratives about generative AI](#)

Fabrizio Gilardi, Atoosa Kasirzadeh, Anita Gohdes

Research Briefing 21 Oct 2024

[A chatbot informed by behavioural science increases vaccination rates more than a simple reminder](#)

A behaviourally informed WhatsApp chatbot that encouraged people in Argentina to get the next dose of the COVID-19 vaccine more than tripled vaccination rates, and nearly doubled them compared to a one-way message reminder. The chatbot has several features built in that helped people to find out where, when and how to get the vaccine.

Article 11 Oct 2024

[Quantifying the use and potential benefits of artificial intelligence in scientific research](#)

Gao and Wang develop a measurement framework that demonstrates the widespread use and benefits of AI in science. Nonetheless, there is a substantial gap between AI education and application across disciplines.

Jian Gao, Dashun Wang

Article 10 Oct 2024

[A behaviourally informed chatbot increases vaccination rates in Argentina more than a one-way reminder](#)

A chatbot informed by insights from behavioural science more than tripled COVID-19 vaccination uptake in Chaco province, Argentina, and nearly doubled it compared with a one-way message reminder.

Dan Brown, Adelaida Barrera, Fernando Torrente

Nature Medicine

Volume 30 Issue 12, December 2024

<https://www.nature.com/nm/volumes/30/issues/12>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 1, January 2025

<https://www.nature.com/nrd/volumes/24/issues/1>

Comment 23 Sept 2024

[The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships](#)

The AMR Accelerator is an Innovative Medicines Initiative programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building antimicrobial resistance research capability. Five years in, we reflect on the programme's value, results and key challenge: ensuring the sustainability of assets, infrastructures and expertise.

Josepine Fernow, Marie Olliver, Anders Karlén

Review Article 04 Nov 2024

[The state-of-the-art of *N*-of-1 therapies and the IRDiRC *N*-of-1 development roadmap](#)

A very small number of people with rare diseases caused by unique genetic variants have been treated with therapies developed specifically for them, known as *N*-of-1 therapies. This Review discusses advances and challenges for *N*-of-1 therapies based on cases in which they have been

successfully developed, highlights why the traditional drug development and reimbursement pathway is not fit for purpose in this field, and provides a roadmap for the development of these individualized therapies.

Anneliene H. Jonker, Elena-Alexandra Tataru, Annemieke Aartsma-Rus

Nature Reviews Genetics

Volume 26 Issue 1, January 2025

<https://www.nature.com/nrg/volumes/26/issues/1>

[New issue; No digest content identified]

Nature Reviews Immunology

Volume 25 Issue 1, January 2025

<https://www.nature.com/nri/volumes/25/issues/1>

[New issue; No digest content identified]

New England Journal of Medicine

Volume 392 No. 2 January 9, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

Nature Biotechnology

Volume 42 Issue 12, December 2024

<https://www.nature.com/nbt/volumes/42/issues/12>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 11 Jan 2025)

[Reviewed earlier]

Nature Genetics

Volume 56 Issue 12, December 2024

<https://www.nature.com/ng/volumes/56/issues/12>

[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 11, November 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/11>

[Reviewed earlier]

Nature Medicine

Volume 30 Issue 12, December 2024

<https://www.nature.com/nm/volumes/30/issues/12>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 12, December 2024

<https://www.nature.com/nrd/volumes/23/issues/12>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 12, December 2024

<https://www.nature.com/nrg/volumes/25/issues/12>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 12, December 2024

<https://www.nature.com/nri/volumes/24/issues/12>

[Reviewed earlier]

New England Journal of Medicine

Volume 392 No. 2 January 9, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 3 No. 12 December 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 11 Jan 2025]

[No new digest content identified]

Pediatrics

Volume 155, Issue 1 1 January 2025

<https://publications.aap.org/pediatrics/issue/155/1>

[Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 12 December 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-12>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 11 Jan 2025)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 11 Jan 2025)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 11 Jan 2025)

[Moving toward universal health coverage with a national health insurance program: A scoping review and narrative synthesis of experiences in eleven low- and lower-middle income countries](#)

Marine Flourence, Eva Jarawan, Mara Boiangiu, Fatima El Kadiri El Yamani

Research Article | published 09 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003651>

["Fear of the unknown": Health, disability, and stakeholder perspectives on the behavioral and social drivers of vaccination in children with disability in Fiji](#)

Rosalie Power, Unise Vakaloloma, Israt Jahan, Sureni Perera, Ilisapeci Tuibeqa, Rachel Devi, Litiana Volavola, William May, Donald Wilson, Lanieta Tuimabu, Gulam Khandaker, Meru Sheel, on behalf of Australian Immunisation and Disability Investigators

Research Article | published 08 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004132>

[It won't end with COVID: Countering the next phase of American antivaccine activism 2025–29](#)

Peter Hotez

Opinion | published 08 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004020>

[Countries' progress towards Global Health Security \(GHS\) increased health systems resilience during the Coronavirus Disease-19 \(COVID-19\) pandemic: A difference-in-difference study of 191 countries](#)

Tyler Y. Headley, Sooyoung Kim, Yesim Tozan

Research Article | published 07 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0004051>

[Long-term impact of 10-valent pneumococcal conjugate vaccine among children <5 years, Uganda, 2014–2021](#)

Mercy Wendy Wanyana, Richard Migisha, Patrick King, Lilian Bulage, Benon Kwesiga, Daniel Kadobera, Alex Riolexus Ario, Julie R. Harris

Research Article | published 06 Jan 2025 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002980>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 11 Jan 2025)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 11 Jan 2025)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 11 Jan 2025]

[Understanding uptake of the COVID-19 vaccination among the homeless: A mixed methods evaluation](#)

Grace Phillips, Emmy Racine, Anna Marie Naughton, Julieann Lane, Patricia M. Kearney

Research Article | published 08 Jan 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0312617>

[Vaccine hesitancy among health paraprofessionals: A mixed methods study](#)

Madeline Hergott, Michael Andreski, John Rovers

Research Article | published 07 Jan 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0312708>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 11 Jan 2025]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

January 14, 2025 | vol. 122 | no. 2

<https://www.pnas.org/toc/pnas/122/2>

[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 11, November 2024

<https://academic.oup.com/pnasnexus/issue/3/11>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 4 - August 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Preventive Medicine

Volume 189 December 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/189/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

December 2024 Volume 291 Issue 2036

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 237 Pages 1-466 (December 2024)

<https://www.sciencedirect.com/journal/public-health/vol/237/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 17, Issue 3, November 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 6, November/December 2024

<https://journals.sagepub.com/toc/phrg/139/6>

[Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 1, January 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 11 Jan 2025]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 44, Issue 12 Pages: 2755-2934 December 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

Special Issue: Risk Science Foundations and COVID

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 11 Jan 2025]

[No new digest content identified]

Science

Volume 387| Issue 6730| 10 Jan 2025

<https://www.science.org/toc/science/current>

[No new digest content identified]

Science and Engineering Ethics

Volume 30, Issue 6 December 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-6>

[Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 780| 8 Jan 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 11 Jan 2025]

[No new digest content identified]

Social Science & Medicine

Volume 364 January 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/364/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>
[Accessed 11 Jan 2025]
[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 6 December 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-6>
[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 62 November–December 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/62/suppl/C>
[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 12 Pages: i-iv, 991-1062 December 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>
[Reviewed earlier]

Vaccine

Volume 44 12 January 2025

<https://www.sciencedirect.com/journal/vaccine/vol/44/suppl/C>

Editorial No access

[Reflections on two decades at the helm and the evolving landscape of scientific publishing](#)

Gregory A. Poland

Article 126534

Editorial No access

[Addressing vaccine misinformation: The critical need for complete product information disclosure](#)

Peter J. Pitts, Gregory A. Poland

Article 126558

Discussion

[No person left behind: Understanding vaccine hesitancy in low- and middle-income countries](#)

Alvira Tyagi, Simar S. Bajaj, Esther Njinembo Naye, Fatima Cody Stanford

Article 126446

Review article Open access

[Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and middle-income countries: A systematic review of qualitative evidence and thematic synthesis](#)

Alice Blukacz, Alexandra Obach, Paola Vásquez, Carla Campaña, ... Báltica Cabieses

Article 126546

Review article Open access

[The evidence base for rotavirus vaccination in India: Current status, future needs](#)

Niranjan Bhat, Elisabeth Vodicka, Allison Clifford, Kanduri Balaji Ananth, ... Gagandeep Kang

Article 126551

Review article Open access

[Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A scoping review of the literature](#)

Claudia Cosma, Alessio Radi, Rachele Cattano, Patrizio Zanobini, ... Marco Del Riccio

Article 126559

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 11 Jan 2025]

Open Access Review

[Exploring Future Pandemic Preparedness Through the Development of Preventive Vaccine Platforms and the Key Roles of International Organizations in a Global Health Crisis](#)

by Jihee Jeon and Eunyong Kim

Vaccines 2025, 13(1), 56; <https://doi.org/10.3390/vaccines13010056> - 10 Jan 2025

Abstract

Background: The emergence of more than 40 new infectious diseases since the 1980s has emerged as a serious global health concern, many of which are zoonotic. In response, many international organizations, including the US Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the European Center for Disease Prevention and Control (ECDC), have developed strategies to combat these health threats. The need for rapid vaccine development has been highlighted by Coronavirus disease 2019 (COVID-19), and mRNA technology has shown promise as a platform. While the acceleration of vaccine development has been successful, concerns have been raised about the technical limits, safety, supply, and distribution of vaccines...

Value in Health

December 2024 Volume 27 Issue 12 p1635-1804

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 185 January 2025

<https://www.sciencedirect.com/journal/world-development/vol/184/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 11 Jan 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2501.01447 [pdf, other]

Analyzing Country-Level Vaccination Rates and Determinants of Practical Capacity to Administer COVID-19 Vaccines

Sharika J. Hegde, Max T.M. Ng, Marcos Rios, Hani S. Mahmassani, Ying Chen, Karen Smilowitz

The COVID-19 vaccine development, manufacturing, transportation, and administration proved an extreme logistics operation of global magnitude. Global vaccination levels, however, remain a key concern in preventing the emergence of new strains and minimizing the impact of the pandemic's disruption of daily life. In this paper, country-level vaccination rates are analyzed through a queuing framework to extract service rates that represent the practical capacity of a country to administer vaccines. These rates are further characterized through regression and interpretable machine learning methods with country-level demographic, governmental, and socio-economic variates. Model results show that participation in multi-governmental collaborations such as COVAX may improve the ability to vaccinate. Similarly, improved transportation and accessibility variates such as roads per area for low-income countries and rail lines per area for high-income countries can improve rates. It was also found that for low-income countries specifically, improvements in basic and health infrastructure (as measured through spending on healthcare, number of doctors and hospital beds per 100k, population percent with access to electricity, life expectancy, and vehicles per 1000 people) resulted in higher vaccination rates. Of the high-income countries, those with larger 65-plus populations struggled to vaccinate at high rates, indicating potential accessibility issues for the elderly. This study finds that improving basic and health infrastructure, focusing on accessibility in the last mile, particularly for the elderly, and fostering global partnerships can improve logistical operations of such a scale. Such structural impediments and inequities in global health care must be addressed in preparation for future global public health crises.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 11 Jan 2025]

[No new digest content identified]

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 11 Jan 2025]

[Filter: All articles]

Characteristics of individuals who received a complete, 2-dose mpox vaccine regimen as part of the public health response to the mpox epidemic in Ontario, Canada: A CIRN study

Ramandip Grewal, Cindy Lau, Jeffrey C Kwong, Ann N Burchell, Lindsay Friedman, Christine Navarro, Evaenzi Okpokoro, Darrell H S Tan, Austin Zygmunt, Sharmistha Mishra, Sarah A Buchan
medRxiv 2025.01.09.25320269; doi: <https://doi.org/10.1101/2025.01.09.25320269>

Sanitation-related empowerment resources are associated with women's well-being, anxiety, and depression: findings from Bangladesh, India, Senegal, and Uganda

Thea Mink, Madeleine Patrick, Amelia Conrad, Tanvir Ahmed, Srishty Arun, Vinod Ramanarayanan, Niladri Chakraborti, Y. Malini Reddy, Abhilaasha Nagarajan, Tanushree Bhan, Sheela S. Sinharoy, Bethany A. Caruso
medRxiv 2025.01.08.25320223; doi: <https://doi.org/10.1101/2025.01.08.25320223>

Climate Change and Malaria: A Call for Robust Analytics

Daniel J Laydon, David L Smith, Kaustubh Chakradeo, Mark P Khurana, Jaffer Okiring, David A Duchene, Samir Bhatt
medRxiv 2024.09.16.24313623; doi: <https://doi.org/10.1101/2024.09.16.24313623> *Revision*

Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden

Josephine Malinga, Lydia Braunack-Mayer, Thiery Masserey, Aurélien Cavelan, Daniel Chandramohan, Alassane Dicko, Jean-Bosco Ouédraogo, Sherrie L Kelly, Epke A Le Rutte, Narimane Nekkab, Melissa A Penny
medRxiv 2024.11.12.24317082; doi: <https://doi.org/10.1101/2024.11.12.24317082> *Revision*

Evaluation of Guillain-Barré syndrome following Respiratory Syncytial Virus Vaccination among Medicare Beneficiaries 65 Years and Older

Patricia C. Lloyd, Purva B. Shah, Henry T. Zhang, Nimesh Shah, Narayan Nair, Zhiruo Wan, Mao Hu, Tainya C. Clarke, Meng Chen, Xinxin Lin, Rose Do, Jing Wang, Yue Wu, Yoganand Chillarige, Richard A. Forshee, Steven A. Anderson
medRxiv 2024.12.27.24319702; doi: <https://doi.org/10.1101/2024.12.27.24319702>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
Selected Research
Preprint

Investigating Public Attitudes Toward AI-Driven Medical Technologies: A Review of Literature on Trust and Ethical Considerations

Olivia Grace and Jesse Drummond

Date created: 2025-01-06 Date modified: 2025-01-08

Abstract

AI can bring about revolutions in health care through improvements in diagnosis and treatment of diseases while ensuring more operational efficiencies. The proposed literature review is intended to build on public perception, trust factors, and some ethical implications of AI-powered medical technologies. Findings indicated general awareness of AI in health, though different depths among participants were noted. AI technologies have various advantages, including improvements in diagnosis, identifying treatment options. However, several issues related to the use of AI in treatment, including data privacy and security concerns, are still looming large in regard to the erosion of human touch in patient care. Transparency, explain ability, reliability, and accuracy are the distinguishing factors for trusting AI. Ethical challenges related to AI algorithms showing bias and the need for informed consent further add to the complications for integrating AI into health. A socially responsible approach toward handling all these issues and ethical guidelines will be vital for successfully introducing AI into health. The involvement of health professionals in developing and implementing the AI system would ensure systems that are user-friendly and meet the requirements in clinical environments. The health sector will, therefore, be able to implement the potentials of AI with integrity only by responding to issues of the public's concern and ethical issues surrounding the technology. Indeed, the future area of study shall address how to reduce bias in AI algorithms, create ethics guidelines, and deduce the long-run implications for patient benefit and healthcare delivery.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 11 Jan 2025]

Research Article Open Access

REVISED - Examining the impact of implementing routine rotavirus vaccination on the number of paediatric admissions due to diarrhoea and dehydration in Kenyan hospitals: A study using interrupted time series analysis.

[version 2; peer review: 3 approved with reservations]

Previous title: The effect of introduction of routine immunization for rotavirus vaccine on paediatric admissions with diarrhoea and dehydration to Kenyan Hospitals: an interrupted time series study

Daisy Chelangat, et al. for Clinical Information Network Author Group

Abstract

Background

Dehydration secondary to diarrhoea is a major cause of hospitalization and mortality in children aged less than five years. Most diarrhoea cases in childhood are caused by rotavirus, and routine introduction of rotavirus vaccine is expected to reduce the incidence and severity of dehydration secondary to diarrhoea in vaccinated infants. Previously, studies have examined changes in admissions with stools positive for rotavirus but this study reports on all admissions with dehydration secondary to diarrhoea regardless of stool rotavirus results. We aimed to assess the changes in all-cause severe diarrhoea and dehydration (DAD) admissions following the vaccine's introduction.

* * * *

Think Tanks

Brookings [to 11 Jan 2025]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 11 Jan 2025]

<https://www.cgdev.org/>

All Research

No new digest content identified.

Chatham House [to 11 Jan 2025]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 11 Jan 2025]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 11 Jan 2025]
<https://www.csis.org/Reports/Selected>
No new digest content identified.

Kaiser Family Foundation [to 11 Jan 2025]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute [to 11 Jan 2025]
<https://www.mckinsey.com/mgi/overview>
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 11 Jan 2025]
<https://odi.org/en/publications/>
Publications [Selected]
No new digest content identified.

Pew Research Center [to 11 Jan 2025]
<https://www.pewresearch.org/>
Latest Publications [Selected]
No new digest content identified.

Rand [to 11 Jan 2025]
<https://www.rand.org/pubs.html>
Published Research [Selected]
Commentary Jan 6, 2025

Dune and Decisionmaking: The Classic's Sci Fi Connection with RAND

Denis Villeneuve's "Dune: Part II" parallels RAND's Robust Decision Making (RDM) approach to policy analysis. Just as spice unlocks Paul Atreides' potential, RDM helps navigate deep uncertainty by exploring multiple futures to inform robust policy strategies, ensuring effective decisionmaking.

Urban Institute [to 11 Jan 2025]
<https://www.urban.org/publications>
New Research Publications - Selected

World Economic Forum [to 11 Jan 2025]
<https://agenda.weforum.org/press/>
Media [Selected]
Global Cooperation at a Crossroads: Possibility amid Rising Geopolitical Uncertainty
News 07 Jan 2025

:: The Global Cooperation Barometer indicates that international cooperation has “flatlined”, driven by heightened geopolitical tensions and instability, but positive momentum in climate finance, health and innovation offers hope.

:: In an era of heightened volatility, leaders will need to embrace “disordered” cooperation and dynamic, solutions-driven decision-making to deliver tangible results and build trust.

:: AI and other emerging technologies are reshaping the global landscape and driving upheaval. Concerted cooperation will be critical to harness benefits and minimize risks.

:: Discover the Barometer and read the accompanying report [here](#).

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *